Hilario Martínez-Barros

Hilario Martínez-Barros

Auto-generated profile, based on publicly available information

Hilario Martínez-Barros

Hospital Universitario Ramón y Cajal, IRYCIS

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2021 in Nutrition
Verified
Journal Article
Closed access
FAFrancisco Arrieta
Francisco Arrieta
VMVictoria Martinez-Vaello
Victoria Martinez-Vaello
NBNuria Bengoa
Nuria Bengoa
LJLucía Jiménez-Mendiguchia
Lucía Jiménez-Mendiguchia
MRMarta Rosillo
Marta Rosillo
Jose Botella-CarreteroJose Botella-Carretero
Jose Botella-Carretero

13 January 2022 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MVManuel Vélez-Díaz-Pallarés
Manuel Vélez-Díaz-Pallarés
BMBeatriz Montero-Llorente
Beatriz Montero-Llorente
MPMaría Ángeles Parro-Martín
María Ángeles Parro-Martín
HMHilario Martínez-Barros
Hilario Martínez-Barros
LCLuis Máiz Carro
Luis Máiz Carro
AÁAna Álvarez-Díaz
Ana Álvarez-Díaz

7 March 2024 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
PDF file
JFJorge Fernández Fradejas
Jorge Fernández Fradejas
HMHilario Martínez-Barros
Hilario Martínez-Barros
LRLourdes Rexach-Cano
Lourdes Rexach-Cano
AÁAna María Álvarez-Díaz
Ana María Álvarez-Díaz
EDEva Delgado-Silveira
Eva Delgado-Silveira
Objectives This study aimed to explore the prevalence of potentially inappropriate medications (PIMs) in a cohort of older adults with advanced cancer referred to palliative care. Secondary objectives were to describe the categories of identified PIMs and assess risk factors associated with their presence in this population. Methods This retrospective, observational study evaluated patients with advanced cancer admitted to a tertiary university hospital in Madrid, Spain and referred to palliative care between 1 January 2020 and 30 June 2020. Demographic, clinical, and pharmacotherapeutic data were obtained from the electronic medical records and regional databases. PIMs were assessed using the Screening Tool of Older Persons Prescriptions in Frail adults (STOPPFrail) criteria, V1. Results Among 123 patients (median age 80 years (IQR 73.5–87), 64.2% male), 74% presented at least one PIM according to the STOPPFrail criteria. The most common categories of inappropriate medications were lipid-lowering therapies, proton pump inhibitors, calcium supplements, and oral antidiabetics. The number of chronic comedications was significantly associated with PIM presence. Conclusions Our study found a high prevalence of PIM among a cohort of older adults with advanced cancer and short life expectancy. This underlines the need for a comprehensive medication review to optimise pharmacotherapy in this population.

3 February 2023 in European Journal of Hospital Pharmacy
Verified
Journal Article
Closed access
PDF file
MMMaría Muñoz-García
María Muñoz-García
HMHilario Martínez-Barros
Hilario Martínez-Barros
SSSilvia Sánchez-Cuéllar
Silvia Sánchez-Cuéllar
AMAna Morales-Tirado
Ana Morales-Tirado
ADAna De-Andrés-Martín
Ana De-Andrés-Martín
DGDavid Gonzalez-de-Olano
David Gonzalez-de-Olano
Severe asthma has an important impact on patients and healthcare resources. Recently, the new specific treatments have defined a new scenario in which person-focused care and specialist multidisciplinary teams are necessary. Our Severe Asthma Unit (SAU) started the ASfarMA project along with an external human-centered design company to understand patients’ vision of their illness, treatment, and healthcare experience, and to define the ideal SAU by performing a core group session, in-depth semistructured interviews and co-creation workshop. Herein, a series of tips classified as either ‘transformative solutions’ or ‘quick wins’, according to a value versus effort matrix are presented. Successful implementation of the proposed solutions will be valuable for patients and healthcare professionals, optimising patient care and resources. These findings can also be helpful to other SAUs or other humanisation projects involving complex, chronic and multidisciplinary pathologies.

20 June 2023 in European Journal of Hospital Pharmacy
Verified
Journal Article
Open access
PDF file
LMLucía Quesada Muñoz
Lucía Quesada Muñoz
JFJorge Fernández Fradejas
Jorge Fernández Fradejas
HMHilario Martinez-Barros
Hilario Martinez-Barros
MCMarina Sánchez Cuervo
Marina Sánchez Cuervo
MRMiriam Martín Rufo
Miriam Martín Rufo
JFJavier Saez de la Fuente
Javier Saez de la Fuente
Objectives Evidence on the effectiveness of remdesivir when used in real-life clinical practice is controversial. This study aims to analyse its effectiveness and the factors associated with increased mortality in non-critically ill patients with COVID-19 pneumonia who require supplemental low-flow oxygen and received remdesivir. Methods A retrospective cohort study was conducted at Ramón y Cajal University Hospital (Madrid, Spain) which included all patients treated with remdesivir in our institution during the second pandemic breakout in Spain, from August to November 2020. Treatment with remdesivir was limited to non-critically ill patients with COVID-19 pneumonia requiring low-flow supplemental oxygen, with a treatment duration of 5 days. Results A total of 1757 patients were admitted with COVID-19 pneumonia during the study period, of which 281 non-critically ill patients were treated with remdesivir and included in the analysis. Mortality at 28 days after initiation of treatment was 17.1%. The median (IQR) time to recovery was 9 days (6–15). 104 (37.0%) patients had complications during hospitalisation, with renal failure being the most frequent (31 patients; 36.5%). After adjustment for confounding factors, high-flow oxygen therapy was associated with increased 28-day mortality (HR 2.77; 95% CI 1.39 to 5.53; p=0.004) and decreased 28-day clinical improvement (HR 0.54; 95% CI 0.35 to 0.85; p=0.008). A significant difference in survival and clinical improvement was identified between patients treated with high and low-flow oxygen. Conclusion The 28-day mortality rate in patients treated with remdesivir needing low-flow oxygen therapy was higher than that published in clinical trials. Age and increased oxygen therapy needed after the beginning of treatment were the main risk factors associated with mortality.

27 July 2024 in Farmacia Hospitalaria
Verified
Journal Article
Open access
HMHilario Martínez-Barros
Hilario Martínez-Barros
ÁPÁlvaro Pousada-Fonseca
Álvaro Pousada-Fonseca
JPJorge Pedreira-Bouzas
Jorge Pedreira-Bouzas
ACAna Clopés-Estela
Ana Clopés-Estela
Objective: To describe the authorisations and funding resolutions for new onco-haematological drugs in Spain between 2017 and 2020, as well as the results of their main trials. Methods: Observational, cross-sectional, descriptive study conducted between October and December 2022. Onco-haematology drugs approved by the European Medicines Agency between 2017 and 2020 were included, according to EFPIA patients W.A.I.T Indicator 2021 Survey. Authorisation information was obtained from the main study of the European Public Assessment Report. Data were collected on medicines, their authorisation and main study, benefit shown, cost, and status and time to reimbursement. Results: Forty-one new drugs authorised for 49 indications were identified. More than half (58.5%) were targeted therapies, and 61.2% were for the treatment of solid tumours (61.2%). Most had palliative intent (71.4%) and were indicated in relapsed or refractory disease (55.1%). Of the clinical trials, 57.1% were phase III and 63.3% were randomised. The primary endpoint was overall survival in 16.3%, increasing to 25.8% among randomised clinical trials. Regarding licensed drugs based on response rate, the median response rate was 56.4% [IQI 40–66.3]. In those authorised on the basis of surrogate time-to-event endpoints, the median hazard ratio was 0.54 [IQI 0.38–0.57], and among those using overall survival was 0.71 [IQI 0.59–0.77]. Globally, 22.4% had shown benefit in overall survival, with a median gain of 4 months [IQI 3.6–16.7]. One-third (33.3%) of the indications evaluable according to the European Society for Medical Oncology Magnitude of Clinical Benefit Scale showed substantial clinical benefit. Of the indications, 75.5% were funded, half (48.6%; 36.7% of the total) with restrictions. The median time to funding was 19.5 months [IQI 11.4–29.3]. Conclusions: Most main clinical trials of new onco-haematology drugs approved in Spain used surrogate primary endpoint and, at the time of authorisation, few had shown to prolong overall survival. More than a third were uncontrolled clinical trials. Objetivo: Describir las autorizaciones y resoluciones de financiación de nuevos fármacos onco-hematológicos en España entre 2017 y 2020, así como los resultados de sus ensayos pivotales. Material y métodos Estudio observacional, descriptivo y de corte transversal llevado a cabo entre octubre y diciembre de 2022. Se incluyeron los medicamentos onco-hematológicos aprobados por la Agencia Europea de Medicamentos entre 2017 y 2020, de acuerdo con EFPIA patients W.A.I.T Indicator 2021 Survey. La información de las autorizaciones fue obtenida del apartado estudio principal del Informe de Evaluación Público Europeo (EPAR, por sus siglas en inglés). Se recogieron datos de los fármacos, su autorización y ensayo clínico pivotal, beneficio mostrado, coste, y situación y tiempo hasta la financiación. Resultados: Se identificaron 41 nuevos fármacos autorizados para 49 indicaciones. Más de la mitad (58,5%) eran terapias dirigidas, y el 61,2% para el tratamiento de tumores sólidos (61,2%). La mayoría tenían intención paliativa (71,4%) y estaban indicadas en recaída o enfermedad refractaria (55,1%). El 57,1% de los ensayos clínicos eran fase III y el 63,3% aleatorizados. La variable principal fue la supervivencia global en el 16,3%, aumentando al 25,8% entre los aleatorizados. La mediana de tasa de respuesta fue de 56,4% [IQI 40–66,3] para los fármacos autorizados en base a esta variable de eficacia. La mediana de Hazard Ratio en los autorizados en base a variables subrogadas de tiempo hasta evento fue de 0,54 [IQI 0,38-0,57], y entre los que utilizaron supervivencia global fue 0,71 [IQI 0,59-0,77]. El 22,4% de las indicaciones habían mostrado beneficio en supervivencia global, con una mediana de ganancia de 4 meses [IQI 3,6-16,7]. Un tercio (33,3%) de las indicaciones evaluables según European Society for Medical Oncology Magnitude of Clinical Benefit Scale mostraban beneficio clínico sustancial. El 75,5% de las indicaciones estaban financiadas, la mitad (48,6%; 36,7% del total) con restricciones. La mediana de tiempo hasta la financiación fue de 19,5 meses [IQI 11,4-29,3]. Conclusiones: La mayoría de los ensayos clínicos pivotales de nuevos fármacos onco-hematológicos autorizados en España emplearon variables principales subrogadas y, en el momento de la autorización, pocos habían demostrado prolongar la supervivencia. Más de un tercio eran ensayos clínicos no controlados.